Literature DB >> 29472054

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

Luis E Raez1, Joseph A Pinto2, Alexa B Schrock3, Siraj M Ali3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472054     DOI： 10.1016/j.jtho.2017.10.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

Review 1.  Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.

Authors:  Yan Guan; Zhanshuai Song; Yan Li; Honglin Guo; Junping Shi; Xuemei Zhang; Ming Yao
Journal:  Oncologist       Date:  2019-05-07

2.  Clinical Utility of Next-generation Sequencing in Real-world Cases: A Single-institution Study of Nine Cases.

Authors:  Moonsik Kim; Ji Yun Jeong; Nora Jee-Young Park; Ji Young Park
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 3.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.

Authors:  Xia Wang; Weiwei Peng; Zhimin Zeng; Jing Cai; Anwen Liu
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

5.  Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience.

Authors:  Martin Zacharias; Gudrun Absenger; Karl Kashofer; Robert Wurm; Jörg Lindenmann; Angelika Terbuch; Selma Konjic; Stefan Sauer; Franz Gollowitsch; Gregor Gorkiewicz; Luka Brcic
Journal:  Transl Lung Cancer Res       Date:  2021-11

6.  EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.

Authors:  Alessandro Di Federico; Marco Filetti; Arianna Palladini; Raffaele Giusti; Marta Piras; Andrea De Giglio; Andrea Ardizzoni; Francesco Gelsomino
Journal:  Transl Lung Cancer Res       Date:  2022-03

7.  Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.

Authors:  Guoqing Zhang; Peiyi Xia; Shanshan Zhao; Lulu Yuan; Xiaosu Wang; Xiangnan Li; Jindong Li
Journal:  Oncologist       Date:  2021-08-18

8.  Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.

Authors:  Rui Zhong; Hui Li; Yanling Liu; Shuang Zhang; Jingjing Liu; Zhicheng Huang; Ying Cheng
Journal:  Thorac Cancer       Date:  2019-12-22       Impact factor: 3.500
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.